Thr435
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Thr435  -  NFkB-p65 (human)

Site Information
PTQAGEGtLSEALLQ   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 451422

In vivo Characterization
Methods used to characterize site in vivo:
electrophoretic mobility shift ( 2 ) , mutation of modification site ( 1 , 2 ) , phospho-antibody ( 1 , 2 ) , phosphoamino acid analysis ( 2 ) , western blotting ( 1 , 2 )
Disease tissue studied:
bone cancer ( 1 ) , cervical cancer ( 2 ) , cervical squamous cell carcinoma ( 2 )
Relevant cell line - cell type - tissue:
MEF (fibroblast) [homozygous knockout] ( 1 ) , SiHa (squamous) ( 2 ) , U2OS (bone cell) ( 1 )

Upstream Regulation
Putative upstream phosphatases:
PPP4C (human) ( 2 )
Treatments:
calyculin_A ( 1 ) , TNF ( 1 )

Downstream Regulation
Effects of modification on biological processes:
transcription, inhibited ( 1 )

References 

1

O'Shea JM, Perkins ND (2010) Thr435 phosphorylation regulates RelA (p65) NF-kappaB subunit transactivation. Biochem J 426, 345-54
20001970   Curated Info

2

Yeh PY, et al. (2004) Suppression of MEK/ERK signaling pathway enhances cisplatin-induced NF-kappaB activation by protein phosphatase 4-mediated NF-kappaB p65 Thr dephosphorylation. J Biol Chem 279, 26143-8
15073167   Curated Info